- cafead Jan 29, 2024 at 11:32: AM
via Alto Neuroscience, a Phase 2 biotech developing biomarker-focused therapies for depression and schizophrenia, announced terms for its IPO on Monday.
The Los Altos, CA-based company plans to raise $101 million by offering 6.7 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Alto Neuroscience would command a fully diluted market value of $407 million.
article source
The Los Altos, CA-based company plans to raise $101 million by offering 6.7 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Alto Neuroscience would command a fully diluted market value of $407 million.
article source